GRI Bio, Inc. Common Stock (GRI) Stock Price

GRIStock
$1.9695.43%52W
Market Cap$4.28M
P/E
PEG Ratio
Div yield
Beta-1.21

GRI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.93%
Price vs S&P 500 (4W)22.12%
VGM Score15.72

GRI Earnings Surprise History

Q2 25-36.68est. -36.68
Q3 25-35.84est. -31.08
Q4 25-116.61est. -29.26
Q1 26-1.61est. -3.74
Q2 26-0.91est. -1.20

GRI Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
4.00
4.00

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
GRIGRI Bio, Inc. Common Stock
F$1.96
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About GRI Bio, Inc. Common Stock

GRI Bio is a clinical-stage biotech company developing immunomodulatory therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead program, GRI-0621, is a RAR-beta/gamma dual agonist that modulates immune T cell responses, with an oral tazarotene formulation also in development. The company's pipeline includes GRI-0803, a Type 2 NKT cell agonist designed to treat autoimmune conditions.